Skip to main content

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Web Exclusives - FDA Approvals

On December 3, 2021, the FDA accelerated the approval of the PD-1 inhibitor pembrolizumab (Keytruda; Merck) for the adjuvant treatment of patients aged ≥12 years with stage IIB or stage IIC melanoma, after complete resection. The FDA granted pembrolizumab an orphan drug designation for this indication. Pembrolizumab has been previously approved by the FDA for many oncologic indications.

The efficacy for this indication was evaluated in the KEYNOTE-716 study, a multicenter, randomized (1:1), double-blind, placebo-controlled clinical trial in patients with completely resected stage IIB or stage IIC melanoma. Patients were randomized to pembrolizumab 200 mg or to the intravenous pediatric dose of 2 mg/kg (up to a maximum of 200 mg) every 3 weeks or to placebo for up to 1 year, until disease recurrence or unacceptable adverse events.

The primary end point was investigator-assessed recurrence-free survival (RFS). The first interim analysis demonstrated a significant improvement in RFS in patients who received pembrolizumab versus those who received a placebo (hazard ratio, 0.65; 95% confidence interval, 0.46-0.92; P = .0132). At the time of the analysis, the median RFS was not reached in either arm.

The most common (≥20%) adverse reactions reported with pembrolizumab in the KEYNOTE-716 study were fatigue, diarrhea, pruritus, and arthralgia.

Related Items
Directory of FDA Approvals, August Through December 2023
December 2023 Vol 16, Payers' Guide to FDA Updates published on January 26, 2024 in FDA Approvals
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Ogsiveo First Treatment FDA Approved for Desmoid Tumors
Web Exclusives published on January 2, 2024 in FDA Approvals
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 18, 2023 in FDA Approvals
Last modified: March 22, 2022